Update your location to show providers, locations, and services closest to you.
Cancer Specialist (Oncologist), Hematology and Oncology Specialist
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal,…
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications…
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 * early breast cancer with intermediate or high risk for disease recurrence who completed definitive…
37 publications
2023
BMJ case reports
PubMed • Publisher's site2023
Cancer reports (Hoboken, N.J.)
PubMed • Publisher's site2023
BMJ case reports
PubMed • Publisher's site2023
BMJ case reports
PubMed • Publisher's site2022
Journal of Clinical Oncology
Publisher's site